Eisai Signs Exclusive Agreement to Commercialize NeuroBloc(R) for Europe

Tokyo (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo,
President & CEO: Haruo Naito) announced that the company has signed
on May 14, 2007 (the U.S. Eastern Time) the exclusive agreement with
Solstice Neurosciences, Inc. (Headquarters: Pennsylvania, U.S.,
President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R) , an
injectable form of botulinum toxin type B agent owned by Solstice. In
this new agreement, Eisai gained the commercialization right over a
total of 35 European countries, including the 27 EU countries,
Norway, Iceland, Liechtenstein, Monaco, Switzerland, Croatia,
Turkey, and Russia.

NeuroBloc(R) was approved for Cervical Dystonia through the
centralized procedure by the European Medicines Evaluation Agency
(EMEA) in January 2001 and has been made available in eight European
countries so far. Treatment with NeuroBloc(R) interrupts cholinergic
transmission between nerves and the affected muscle, causing it to
relax.

For the Japanese Market, Eisai signed an exclusive agreement with
Elan Corporation, plc.(x) for the development and marketing right of
this product in September 2000. In December 2006, Eisai filed the
new drug application for this product in Japan for the treatment of
Cervical Dystonia.

Eisai is rapidly enhancing its neurology product lineup in Europe
with its global products including Aricept(R) (symptomatic treatment
of Alzheimer's disease) as well as the anti-epilepsy agents
Zonegran(R) and Inovelon(R). With this strategic alliance for
NeuroBloc(R), Eisai expects to make further contributions to
increasing the benefits to the patients and their families in Europe.

(x) Elan Corporation, plc. sold all assets of NeuroBloc(R) to
Solstice Neurosciences, Inc. in July 2004.

Notes to Editor:

About Cervical Dystonia

Cervical Dystonia is a condition of abnormal muscle tone and
movement that can result in painful abnormalities of posture or
inability to flex and relax affected neck and shoulder muscles. The
botulinum toxin type B compound is effective in the treatment of
cervical dystonia by relaxing affected neck and shoulder muscles
through blocking the neurotransmitter acetylcholine in those
patients responsive to botulinum toxin therapy treatment.

Contact:
Andrew Day
European Director of PR and Communications
Eisai Europe Limited
Tel: +44(0)-208-600-1400

ots Originaltext: Eisai Co., Ltd
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Andrew Day, European Director of PR and Communications,
Eisai Europe Limited, Tel: +44(0)-208-600-1400